|Publication number||US3384541 A|
|Publication date||21 May 1968|
|Filing date||28 Oct 1964|
|Priority date||28 Oct 1964|
|Publication number||US 3384541 A, US 3384541A, US-A-3384541, US3384541 A, US3384541A|
|Inventors||William G Clark|
|Original Assignee||William G. Clark|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (7), Referenced by (70), Classifications (20)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent 3,384,541 SPERMICIDAL VAGINAL PHARMACEUTICAL CONCENTRATE FOR PRODUCENG NON- AQUEOUS FOAM WITH AEROSOL PROPEL- LANTS William G. Clark, 1142 Las Pulgas Road, Pacific Palisades, Calif. 90272 No Drawing. Filed Oct. 28, 1964, Ser. No. 407,231 1 Claim. (Cl. 167-58) ABSTRACT OF THE DISCLOSURE The invention provides a new composition of matter comprising a major proportion of propylene glycol in a minor proportion of an ethoxylated tallow alcohol, the composition being adapted to incorporation in foam-producing assemblies.
This invention relates to a new and useful non-aqueous foam-producing pharmaceutical substance, and more particularly to such a substance adapted for use as a medicant in a self-propelled dispenser using fluorinated hydrocarbons or other aerosol propellants.
There is a need for a simple, easily used single-dose contraceptive which can be applied as an aerosol foam into the vaginal canal. There has also been a need for a pharmaceutical vehicle for medicants adapted to be injected into human body cavities that can be used either with or without water, depending upon the stability of the ingredients to be incorporated into the preparation. Thus, it is desirable to have a single base that can be used with various enzymes, antibiotics, and medicinal agents, with or without spermicidal agents.
Accordingly, it is a primary object of the present invention to provide a newand useful non-aqueous foamproducing vehicle.
Another object of the invention is to provide a vehicle of the type described in combination with spermicidal substances.
Another object of the present invention is to provide a foam-producing vehicle that can be used either with or without water and various enzymes, antibiotics, and spermicidal agents.
Yet another object .of the present invention is to provide a new and useful non-aqueous foam-producing vehicle which contains ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, Wetting agent, and viscosity builder.
A further object of the present invention is to provide a vehicle of the type described which is also spermicidal.
A still further object of the present invention is to provide a vehicle of the type described which is especially suited for use in and in combination with aerosol type applicators for injecting medicants into human body cavities.
A medicinal application of this type is shown and claimed in copending application Ser. No. 407,170, filed Oct. 28, 1964, by the instant inventor, now abandoned.
The non-aqueous foam-producing pharmaceutical substance of the present invention includes a vehicle containing ethoxylated tallow alcohol as a foaming agent, emulsifier, detergent, wetting agent, and viscosity builder. The
3,384,541 Patented May 21, 1968 "ice ethoxylated alcohol is a condensate of pressure-hydrogenated tallow alcohol. The general formula is with R being a combination of CH (CH CH OH (stearyl alcohol 62%), CH (CH CH OH (cetyl alcohol 33%), and CH (CH CH OH (myristyl alcohol 5%) and the x ranging from three to eleven moles of ethylene oxide.
Propylene glycol U.S.P. may serve as a solvent, preservative, and emollient, and propylhydroxyparaben U.S.P. and methylhydroxyparaben U.S.P. are used as preservatives. In preparing the vehicle, grams of propylene glycol U.S.P'. are heated to approximately 50 degrees C. and 0.4 gram of methylhydroxyparaben plus 0.2 grain of propylhydroxyparaben are added and stirred. Two grams of ethoxylated tallow alcohol containing three moles of ethylene oxide, oil-soluble type, are heated to 50 degrees C., and combined with the propylene glycol preservative combination. Ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide may be used in this formula, depending upon the consistency of foam desired. The product is allowed to cool, and a sufficient amount of propylene glycol U.S.P. is added to make the product weigh 50 grams. Other glycols, as well as glycerol can be used in place of propylene glycol.
Spermicidal preparations are made from this vehicle, as described in the following examples, by dissolving the active ingredients in a sufiicient amount of propylene glycol U.S.P. to make 50 grams, and the resulting product is combined with 50 grams of the vehicle to make grams of spermicidal foam concentrate. In some cases, heat must be employed to effect solution. Heat labile substances must be added after cooling.
The non-ionic nature of the vehicle makes possible the addition of cationic or anionic substances without affecting the foam-producing and barrier action of the ingredients. Propylene glycol is an excellent solvent for many organic chemicals. Its solubility with water in all proportions makes possible the addition of aqueous solutions of spermicidal agents. This vehicle mixes quickly with seminal fluid and vaginal secretions, permitting rapid action of the active ingredients. Its surfactant action spreads the spermicide into all surfaces and crevices. The non-aqueous nature of the vehicle minimizes variations in action due to individual variations of moisture present. The viscous base and foam provide barrier action to passage of sperm through the cervix.
The vehicle itself is spermicidal as shown by the Sanderson-Cramer method of spermicidal evaluation. The vehicle, when diluted with two parts of buffered fructose solution, kills human sperm in twenty seconds. The buffered fructose solution contained three percent fructose, 0.24% anhydrous phosphate, 0.01% mono potassium phosphate, 0.2% sodium chloride, and distilled water (q.s.).
When diluted with an equal volume of propylene glycol U.S.P., the vehicle of the present invention produces a foam with propellants from an aerosol container of the types shown and described in said copending application. A partial emulsification results when the foam concentrate is shaken with fluorinated hydrocarbons or other aerosol propellants. When released in the manner described in said copending application, an excellent foam is produced. The ratio of vehicle to added propylene glycol can be altered to vary the foam consistency or to compensate for viscosities of added substances. Because of the insolubility of the ethoxylated tallow alcohols in water, the latter can be added to stiffen the foam where it does not affect the stability of added substances.
The formulation has been shown to be non-toxic to the mucosa of the human vagina and cervix. An amount in excess of that ordinarily used, namely grams of the liquid foam concentrate, was applied to the cervical mucosa of six oflice patients and examination made the next morning. No indications of inflammation were seen, even on repeated application.
The vehicle of the present invention is stable over long periods of time and maintains the stability of added ingredients which are unstable in aqueous vehicles of the prior art.
The following are typical examples of the non-aqueous foam-producing pharmaceutical substance of the present invention:
EXAMPLE 1 EXAMPLE 2 The product of Example 1 was prepared in the manner of Example 1 except that the ethoxylated tallow alcohol contained four moles of ethylene oxide.
EXAMPLE 3 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained five moles of ethylene oxide.
EXAMPLE 4 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained six moles of ethylene oxide.
EXAMPLE 5 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained seven moles of ethylene oxide.
EXAMPLE 6 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eight moles of ethylene oxide.
EXAMPLE 7 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained nine moles of ethylene oxide.
EXAMPLE 8 The product of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained ten moles of ethylene oxide.
EXAMPLE 9 The produce of Example 1 was prepared in accordance with the steps of Example 1 except that the ethoxylated tallow alcohol contained eleven moles of ethylene oxide.
EXAMPLE 10 A product was prepared in accordance with each of the preceding examples except that, in each case, eighty grams 1 of glycerol USP were used in place of the propylene glycol.
EXAMPLE 11 Grams Aliphatic polyoxyethylene ether (100% active.
Made from commercial tridecyl alcohol and ethylene oxide to give material with an inverse cloud point of approximately 40-42 C. The material is made by standard ethoxylation technique) 5 The vehicle of Example 1 50 Propylene glycol q.s. ad 100 The aliphatic polyoxyethylene ether provides an excellent spermicide. Its non-ionic nature permits its combination with anionic or cationic agents without any change in spermicidal or antibiotic power. This composition produces an excellent foam when combined with propellants in aerosol containers. The ratio of propylene glycol to vehicle can be altered to produce varied consistency of foam.
EXAMPLE 12 Grams Aliphatic polyoxyethylene ether (100% active, de-
scribed in Example 11) 5 Lactic acid U.S.P. 0.5 Distilled water 10 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s. ad
Sufiicient acid has been added to this product to produce a pH of 4.0 which increases the spermicidal power because it produces a condition resembling the vaginal pH of 4.5. Water has been added to aid in the ionization of the acid because the effect of acids in spermicides depends upon the extent to which they ionize.
EXAMPLE 13 Grams Aliphatic polyoxyethylene ether (100% active, de-
scribed in Example 11) 5 Papain 1 Vehicle of Example 2 50 Propylene glycol U.S.P. q.s. ad 100 EXAMPLE 14 Grams Aliphatic polyoxyethylene ether (100 active, de-
scribed in Example 11) 5 Trypsin 1 Vehicle of Example 3 50 Propylene glycol U.S.P. q.s. ad 100 Other pancreatic enzymes that could be used in the foam concentrate include cathepsins and chymotrypsin.
EXAMPLE l5 Grams Aliphatic polyoxyethylene ether of Example 11 5 Desoxyribonucleases (a Dornase proteolytic enzyme) 1 Vehicle of Example 4 50 Propylene glycol U.S.P. q.s. ad 100 Bacterial protease from B. Subtz'lis 1 Vehicle of Example 5 50 Propylene glycol U.S.P. q.s. ad 100 Other proteases from microbiological sources included those from Pseudomonas, Clostridia, and fungi. Hyaluronidase also has been used. The proteolytic enzymes described in Examples 13 through 16 enhance the mucolytic action upon sperm as well as vaginal and cervical mucous, allowing the spermicide to reach the sperm better. The cleansing and anti-inflammatory, antibioticenhancing, fibrinolytic, mucolytic, and debriding properties of such enzymes is known. Thus, they can be used in vehicles of the present invention for intravaginal infestations such as vaginitis, leukorrhea, trichomonas, moniliasis, as well as for hygienic and prophylactic purposes by incorporating them alone or in combination with suitable antiseptics, germicides, antibiotics, and peptizing agents such as carbamide. Water has been omitted in Examples 13 through 16 to increase the stability of the enzymes and antibiotics. Stability studies have shown that enzymes retain over 50% of their proteolytic activity against standard substrates when left at room temperature for six months.
Propylene glycol U.S.P. q.s. ad 100 This combination was formulated for instances where a contraceptive is desired in combination with trichomonal or other antibiotic or where the latter is desired alone in an aerosol foam treatment. It is known that Tyrothricin and Chlortetracycline are more active protozoal agents than streptomycin, chloramphenicol, or penicillin. Tyrothricin possesses many advantages over other antibiotics for use in the vehicle of the present invention. It is odorless and has remarkable stability, being stable in aqueous solutions and propylene glycol for long periods even at summer temperatures. Its solution in propylene glycol may be autoclaved without significant loss of activity. Its solubility in propylene glycol and its compatibility with many organic and inorganic substances makes it uniquely useful with a spermicidal composition. Lactic acid has been added to this composition to maintain a healthier flora in the vagina. As is known, the treatment of trichomonas vaginalis is directed toward cleanliness and maintenance of acid pH in the vagina. Water has been added to the formula to aid in the ionization of the acid.
EXAMPLE l8 Grams Aliphatic polyoxyethylene ether of Example 11 5 Tyrothricin 0.5 Papain 1 Vehicle of Example 7 50 Propylene glycol q.s. ad 100 can be expected in vivo that do not show in this test because of the enhanced action of the added enzymes and acids. No appreciable difference in spermicidal action was noted with the addition of antibiotics in vitro.
EXAMPLE 19 Grams Aliphatic polyoxyethylene ether of Example 11 5 Hydrocortisone alcohol, micronized 1 Vehicle of Example 8 50 Propylene glycol q.s. ad
Hydrocortisone can be used along with the contraceptive when its anti-inflammatory action is desired. The relative insolubility and its high degree of activity of the alcohol form make it useful, especially where the systemic effects of the glucocorticoid are not desired.
EXAMPLE 20 Grams Aliphatic polyoxyethylene ether of Example 1 5 Hydrocortisone alcohol, micronized 1 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Glycerol q.s. ad 100 This formula combines the anti-inflammatory qualities of Hydrocortisone with the anti-pyogenic action of neomycin plus contraceptive.
EXAMPLE 21 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 Other sulfonamides may be used in place of the sulfanilamide or a combination of two or more may be used. This formula is useful in the post-operative care of the cervix and for secondary invasions of trichomonas vaginalis.
EXAMPLE 22 Grams Aliphatic polyoxyethylene ether of Example 11 5 Sulfanilamide, micronized 10 Neomycin sulfate, micronized 0.5 Vehicle of Example 1 50 Propylene glycol U.S.P. q.s.d. ad 100 This formula can be used when the action of a sulfonamide along with an antibiotic is desired plus contraceptive. Another sulfonamide or sulfonamides may be used as well as antibiotics.
EXAMPLE 23 Grams Aliphatic polyoxyethylene ether of Example 11 5 Povidone iodine NND 1 Vehicle of Example 1 50 Propylene glycol q.s. ad 100 The addition of the iodine compound aids in the treatment of non-specific vaginitis and Candida albicans, Monilia, and T richomonas vaginalis along with a contraceptive.
EXAMPLE 24 Examples were prepared in accordance with each of the thirteen preceding examples (ll-23) execept that in each case the aliphatic polyoxyethylene ether was omitted.
While the particular embodiments of the present invention herein described in detail are fully capable of attaining the objects and providing the advantages hereinbefore stated, it is to be understood that they are merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended to the specific embodiments herein described other than as defined in the appended claim.
1. A spermicidal vaginal pharmaceutical concentrate for producing non-aqueous foam with aerosol propellants comprising:
80 grams of propylene glycol;
0.4 gram of methylhydroxyparaben;
0.2 gram of propylhydroxyparaben; I
2 grams of ethoxylated tallow alcohol containing from three to eleven moles of ethylene oxide of the oilsoluble type; said composition of matter being nonaqueous, thereby constituting a stable vehicle for proteolytic enzymes and antibiotics.
References Cited UNITED STATES PATENTS 2,854,377 9/1958 Elias 16758 2,943,979 7/1960 Elias 167-58 3,055,834 9/1962 Charle et a1. 25290 8 3,131,152 4/1964 Klausner 252-305 3,219,525 11/1965 Berkow 167-58 3,240,396 3/ 1966 Friedenberg 222-146 3,244,589 4/ 1966 Sunnen et a1 167-58 OTHER REFERENCES McCutcheon, John W.: D & E, 1963, Detergents and Emulsifiers, 1963, Annual pub., 1963, Morristown, N.J., pp.: cover, inside front cover, 31, 33, 45, 57, 58, 62, 63, 86, 87, 112, 116, 131, 135.
Federal Register 30 (228): 14639 Nov. 25, 1965, Dimethyl Sulfoxide (DMSO) Preparations, Termination of Clinical Testing and Investigational Use.
Ferm: Teratogenic Efiect of Dimethyl Sulphoxide, Lancet, I, 1966, pp. 208-209, Jan. 22, 1966.
LEWIS GOTTS, Primary Examiner.
SHEP K. ROSE, Examiner.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2854377 *||22 Sep 1955||30 Sep 1958||Nathaniel M Elias||Effervescent compositions containing a surface active agent|
|US2943979 *||23 Jun 1959||5 Jul 1960||Nathaniel M Elias||Concentrated foam-producing spermicides|
|US3055834 *||2 Jun 1958||25 Sep 1962||Oreal||Anhydrous anion-active detergents in the form of aerosols|
|US3131152 *||13 Jun 1960||28 Apr 1964||Allied Chem||Foam producing formulations|
|US3219525 *||16 Jan 1963||23 Nov 1965||Menlo Park Lab Inc||Vaginal douche solution|
|US3240396 *||11 Jun 1963||15 Mar 1966||Robert M Friedenberg||Aerosol dispenser|
|US3244589 *||26 Oct 1962||5 Apr 1966||Sunnen||Alkyl phenoxy polyethoxy ether spermicidal aerosol|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3819528 *||6 Mar 1972||25 Jun 1974||Procter & Gamble||Stabilized aqueous enzyme compositions|
|US3929985 *||18 Jan 1974||30 Dec 1975||Richardson Merrell Inc||Anhydrous candicidin foam compositions|
|US4252787 *||27 Dec 1976||24 Feb 1981||Cambridge Research And Development Group||Anti-fertility composition and method|
|US4310510 *||3 Oct 1980||12 Jan 1982||Sherman Kenneth N||Self administrable anti-fertility composition|
|US4551148 *||11 Oct 1984||5 Nov 1985||Kv Pharmaceutical Company||Vaginal delivery systems and their methods of preparation and use|
|US5266329 *||31 Oct 1985||30 Nov 1993||Kv Pharmaceutical Company||Vaginal delivery system|
|US5340836 *||1 Jun 1992||23 Aug 1994||Mark S. Reinhard||Composition and method for treatment of vaginal yeast infections|
|US5573765 *||13 Aug 1994||12 Nov 1996||Mark S. Reinhard||Composition and method for treatment of vaginal yeast infections|
|US7700076||20 Aug 2004||20 Apr 2010||Foamix, Ltd.||Penetrating pharmaceutical foam|
|US7704518||9 May 2006||27 Apr 2010||Foamix, Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US7820145||28 Apr 2004||26 Oct 2010||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8114385||26 Dec 2006||14 Feb 2012||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8119106||8 Jul 2009||21 Feb 2012||Foamix Ltd||Foamable iodine compositions|
|US8119109||13 Mar 2007||21 Feb 2012||Foamix Ltd.||Foamable compositions, kits and methods for hyperhidrosis|
|US8119150||6 Jul 2006||21 Feb 2012||Foamix Ltd.||Non-flammable insecticide composition and uses thereof|
|US8343945||7 Jun 2010||1 Jan 2013||Foamix Ltd.||Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof|
|US8362091||26 Apr 2010||29 Jan 2013||Foamix Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US8435498||1 Apr 2010||7 May 2013||Foamix Ltd.||Penetrating pharmaceutical foam|
|US8486374||14 Jan 2008||16 Jul 2013||Foamix Ltd.||Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses|
|US8486375||20 Feb 2012||16 Jul 2013||Foamix Ltd.||Foamable compositions|
|US8486376||6 Apr 2005||16 Jul 2013||Foamix Ltd.||Moisturizing foam containing lanolin|
|US8512718||12 Feb 2010||20 Aug 2013||Foamix Ltd.||Pharmaceutical composition for topical application|
|US8518376||6 Oct 2009||27 Aug 2013||Foamix Ltd.||Oil-based foamable carriers and formulations|
|US8518378||14 Sep 2010||27 Aug 2013||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8618081||4 May 2011||31 Dec 2013||Foamix Ltd.||Compositions, gels and foams with rheology modulators and uses thereof|
|US8636982||7 Aug 2008||28 Jan 2014||Foamix Ltd.||Wax foamable vehicle and pharmaceutical compositions thereof|
|US8703105||11 Mar 2013||22 Apr 2014||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US8709385||14 Jul 2010||29 Apr 2014||Foamix Ltd.||Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses|
|US8722021||6 Mar 2013||13 May 2014||Foamix Ltd.||Foamable carriers|
|US8741265||4 Mar 2013||3 Jun 2014||Foamix Ltd.||Penetrating pharmaceutical foam|
|US8795635||12 May 2010||5 Aug 2014||Foamix Ltd.||Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses|
|US8795693||29 Nov 2007||5 Aug 2014||Foamix Ltd.||Compositions with modulating agents|
|US8840869||28 Apr 2005||23 Sep 2014||Foamix Ltd.||Body cavity foams|
|US8865139||9 Jul 2014||21 Oct 2014||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US8871184||1 Oct 2010||28 Oct 2014||Foamix Ltd.||Topical tetracycline compositions|
|US8900553||7 Jun 2010||2 Dec 2014||Foamix Pharmaceuticals Ltd.||Oil and liquid silicone foamable carriers and formulations|
|US8900554||20 Feb 2012||2 Dec 2014||Foamix Pharmaceuticals Ltd.||Foamable composition and uses thereof|
|US8945516||1 Oct 2010||3 Feb 2015||Foamix Pharmaceuticals Ltd.||Surfactant-free water-free foamable compositions, breakable foams and gels and their uses|
|US8992896||27 Aug 2014||31 Mar 2015||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US9050253||7 Apr 2014||9 Jun 2015||Foamix Pharmaceuticals Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US9072667||27 Jan 2012||7 Jul 2015||Foamix Pharmaceuticals Ltd.||Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses|
|US9101662||3 Oct 2013||11 Aug 2015||Foamix Pharmaceuticals Ltd.||Compositions with modulating agents|
|US9161916||31 Dec 2012||20 Oct 2015||Foamix Pharmaceuticals Ltd.||Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof|
|US9167813||27 Jan 2012||27 Oct 2015||Foamix Pharmaceuticals Ltd.||Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses|
|US9211259||7 Jun 2006||15 Dec 2015||Foamix Pharmaceuticals Ltd.||Antibiotic kit and composition and uses thereof|
|US9265725||5 Jul 2007||23 Feb 2016||Foamix Pharmaceuticals Ltd.||Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof|
|US9320705||8 Jan 2009||26 Apr 2016||Foamix Pharmaceuticals Ltd.||Sensation modifying topical composition foam|
|US9439857||1 Dec 2008||13 Sep 2016||Foamix Pharmaceuticals Ltd.||Foam containing benzoyl peroxide|
|US9492412||22 Apr 2014||15 Nov 2016||Foamix Pharmaceuticals Ltd.||Penetrating pharmaceutical foam|
|US9539208||4 Feb 2014||10 Jan 2017||Foamix Pharmaceuticals Ltd.||Foam prepared from nanoemulsions and uses|
|US9549898||2 Oct 2014||24 Jan 2017||Foamix Pharmaceuticals Ltd.||Oil and liquid silicone foamable carriers and formulations|
|US9572775||17 Sep 2015||21 Feb 2017||Foamix Pharmaceuticals Ltd.||Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses|
|US9622947||8 Jan 2009||18 Apr 2017||Foamix Pharmaceuticals Ltd.||Foamable composition combining a polar solvent and a hydrophobic carrier|
|US9636405||11 Mar 2013||2 May 2017||Foamix Pharmaceuticals Ltd.||Foamable vehicle and pharmaceutical compositions thereof|
|US9662298||22 Jan 2014||30 May 2017||Foamix Pharmaceuticals Ltd.||Wax foamable vehicle and pharmaceutical compositions thereof|
|US9668972||11 Mar 2005||6 Jun 2017||Foamix Pharmaceuticals Ltd.||Nonsteroidal immunomodulating kit and composition and uses thereof|
|US9675700||13 Jan 2015||13 Jun 2017||Foamix Pharmaceuticals Ltd.||Topical tetracycline compositions|
|US9682021||25 Feb 2014||20 Jun 2017||Foamix Pharmaceuticals Ltd.||Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses|
|US9713643||8 May 2014||25 Jul 2017||Foamix Pharmaceuticals Ltd.||Foamable carriers|
|US9795564||15 Aug 2013||24 Oct 2017||Foamix Pharmaceuticals Ltd.||Oil-based foamable carriers and formulations|
|US9849142||14 Mar 2013||26 Dec 2017||Foamix Pharmaceuticals Ltd.||Methods for accelerated return of skin integrity and for the treatment of impetigo|
|US20050031547 *||28 Apr 2004||10 Feb 2005||Foamix Ltd.||Oleaginous pharmaceutical and cosmetic foam|
|US20080177075 *||3 May 2005||24 Jul 2008||Aq+Plc Stephen Mabbott Associates||Compositions For Progeny Gender Control|
|US20110045037 *||1 Dec 2008||24 Feb 2011||Foamix Ltd.||Foam containing benzoyl peroxide|
|US20110178162 *||13 Jan 2011||21 Jul 2011||Medical University Of South Carolina||Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy|
|EP1495758A2 *||7 Jan 2000||12 Jan 2005||3M Innovative Properties Company||Formulations and methods for treatment of mucosal associated conditions with an immune response modifier|
|EP1495758A3 *||7 Jan 2000||13 Apr 2005||3M Innovative Properties Company||Formulations and methods for treatment of mucosal associated conditions with an immune response modifier|
|WO1987002576A1 *||31 Oct 1985||7 May 1987||Kv Pharmaceutical Company||Vaginal delivery systems|
|WO1998019545A1 *||6 Nov 1996||14 May 1998||Reinhard Mark S||Composition and method for the treatment of vaginal yeast infections|
|WO2005105090A1 *||3 May 2005||10 Nov 2005||Aq+ Plc||Compositions for progeny gender control|
|U.S. Classification||424/45, 424/94.64, 424/94.3, 424/94.6, 424/94.65, 424/672, 514/967, 514/179, 514/957|
|International Classification||A61K9/12, A61K9/00, C09K3/30|
|Cooperative Classification||C09K3/30, A61K9/122, Y10S514/967, Y10S514/957, A61K9/0034|
|European Classification||C09K3/30, A61K9/12B, A61K9/00M8|